Antidepressants (Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors) in treatment of adults with depression

Q 1: Are antidepressants (Tricyclic Antidepressants (TCA) and Selective Serotonin Reuptake Inhibitors (SSRI)) better (more effective than/as safe as) than treatment as usual (placebo) in adults with depressive episode/disorder?

Background
The relative merits of antidepressants versus placebo for depression have been given considerable scientific attention in recent years. This document covers the use of TCAs and SSRIs as acute phase treatment for depressive episode/disorder.

Population/Intervention(s)/Comparison/Outcome(s) (PICO)

- **Population:** adults with depressive episode/disorder
- **Interventions:** antidepressant medicines: TCAs, SSRIs
- **Comparison:** placebo
- **Outcomes:**
  - treatment effectiveness in terms of reduction of symptoms
  - treatment effectiveness in terms of improvement in functioning
  - acceptability profile
  - suicide related outcomes

List of the systematic reviews identified by the search process

INCLUDED IN GRADE TABLES OR FOOTNOTES
Antidepressants (Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors) in treatment of adults with depression


EXCLUDED FROM GRADE TABLES AND FOOTNOTES


Antidepressants (Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors) in treatment of adults with depression


**PICO Table**

<table>
<thead>
<tr>
<th>Serial no.</th>
<th>Intervention/Comparison</th>
<th>Outcomes</th>
<th>Systematic reviews used for GRADE</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>treatment effectiveness in terms of improvement in functioning</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>acceptability profile</td>
<td>Arroll et al (2005)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>suicide related outcomes</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>suicide related outcomes</td>
<td>Supplementary information was extracted from FDA analysis (Laughren, 2006)</td>
<td></td>
</tr>
</tbody>
</table>
Antidepressants (Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors) in treatment of adults with depression

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td></td>
<td>treatment effectiveness in terms of improvement in functioning</td>
<td>No data</td>
<td>Supplementary information was extracted from FDA analysis (Laughren 2006)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>acceptability profile</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>suicide related outcomes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Narrative description of the studies that went into the analysis**

*Arroll et al (2005)*, who included only studies carried out in the primary health care, analysed 15 studies with 890 participants in SSRI studies, 596 in TCA studies, and 1,267 patients on placebo. Of the 5 possible SSRIs available, 2 studied sertraline, 3 studied escitalopram (a precursor of citalopram), and 1 studied citalopram. Of the TCAs available, 2 studied dothiepin, 4 studied amitriptyline, 2 studied mianserin, and 3 studied imipramine. Ten of the 15 studies were identified as having a competing interest.

*NICE (2004)* included 48 studies comparing one of the SSRIs with placebo (7460 participants). All included studies were published between 1983 and 2003 and were between four and 24 weeks long (mean = 6.75 weeks), with 16 trials of eight weeks or longer. Three studies were of inpatients, 31 of outpatients, one in primary care and 13 either mixed or unspecified. In no study were more than 80% of study participants aged 65 years and over. It was possible to determine baseline severity in 19 studies, with four being classified as moderate, six as severe and nine as very severe. No studies focused on mild depressive episode/disorder.
Antidepressants (Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors) in treatment of adults with depression

GRADE Tables

Table 1

Author(s): Corrado Barbui, Andrea Cipriani
Date: 2009-05-25
Question: Should TCAs vs placebo be used for adults with depressive episode/disorder (in primary health care)?
Settings: nonspecialized health care

<table>
<thead>
<tr>
<th>Quality assessment</th>
<th>No of patients</th>
<th>Summary of findings</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No of studies</td>
<td>Design</td>
</tr>
<tr>
<td>Response on severity of depressive symptoms</td>
<td>8</td>
<td>randomized trials</td>
</tr>
<tr>
<td>Functioning</td>
<td>5</td>
<td>no evidence available</td>
</tr>
<tr>
<td>Suicide related outcomes</td>
<td>1</td>
<td>randomized trials</td>
</tr>
<tr>
<td>Adverse effects leading to withdrawal</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CRITICAL 2021-10-01
Antidepressants (Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors) in treatment of adults with depression

1. From Figure 2 of Arroll et al (2005).
2. Dropout rate exceeded 30% in the majority of studies.
3. Another systematic review included randomized trials comparing low dosage tricyclics (<100 mg/day) with placebo or with standard dosage tricyclics in adults with depression (any settings) (Furukawa et al (2002)). It found that low dosage tricyclics, mostly between 75 and 100 mg/day, were 1.65 (95% confidence interval 1.36 to 2.0) and 1.47 (1.12 to 1.94) times more likely than placebo to bring about response at 4 weeks and 68 weeks, respectively.
4. From Table 15 of FDA analysis. The total number of included studies is not reported.
5. Studies were not primarily designed to assess the risk of suicide-related outcomes.
6. This is a rare outcome that has been inconsistently reported in the included studies.
7. Adults with any psychiatric disorders recruited in any settings are included.
8. The 95% confidence interval includes both no effect and appreciable benefit.
9. Absolute numbers not reported in the FDA analysis.
10. From Figure 4 of Arroll et al (2005).

Table 2

Author(s): Corrado Barbui, Andrea Cipriani
Date: 2009-05-27

Question: Should SSRIs vs placebo be used for adults with depression (any settings)?

Settings:


<table>
<thead>
<tr>
<th>No of studies</th>
<th>Design</th>
<th>Limitations</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Summary of findings</th>
<th>Effect</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depressive symptoms (Better indicated by lower values)</td>
<td>randomized trials</td>
<td>very serious¹</td>
<td>no serious inconsistency</td>
<td>no serious indirectness</td>
<td>no serious imprecision</td>
<td>None</td>
<td>1177</td>
<td>1046</td>
<td>SMD 0.34 lower (0.47 to 0.22 lower)</td>
<td>VERY LOW</td>
<td>CRITICAL</td>
</tr>
<tr>
<td>Lack of response on severity of symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Antidepressants (Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors) in treatment of adults with depression

#### Functioning (Better indicated by lower values)

<table>
<thead>
<tr>
<th>Trials</th>
<th>Randomized</th>
<th>Limitations</th>
<th>Indirectness</th>
<th>Inconsistency</th>
<th>Imprecision</th>
<th>RR</th>
<th>CI</th>
<th>Study Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>no evidence available</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>992/1883 (52.7%)</td>
<td>836/1260 (66.3%)</td>
<td>RR 0.73 (0.69 to 0.78)</td>
</tr>
<tr>
<td>1</td>
<td>randomized</td>
<td>very serious</td>
<td>no serious</td>
<td>no serious</td>
<td>no serious</td>
<td>none</td>
<td>none</td>
<td>none</td>
</tr>
</tbody>
</table>

#### Treatment acceptability (total dropouts)

<table>
<thead>
<tr>
<th>Trials</th>
<th>Randomized</th>
<th>Limitations</th>
<th>Indirectness</th>
<th>Inconsistency</th>
<th>Imprecision</th>
<th>RR</th>
<th>CI</th>
<th>Study Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>no evidence available</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>0</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>1</td>
<td>randomized</td>
<td>no serious</td>
<td>no serious</td>
<td>no serious</td>
<td>no serious</td>
<td>none</td>
<td>none</td>
<td>none</td>
</tr>
</tbody>
</table>

#### Suicide related outcomes

<table>
<thead>
<tr>
<th>Trials</th>
<th>Randomized</th>
<th>Limitations</th>
<th>Indirectness</th>
<th>Inconsistency</th>
<th>Imprecision</th>
<th>RR</th>
<th>CI</th>
<th>Study Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>no evidence available</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>0</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>1</td>
<td>randomized</td>
<td>very serious</td>
<td>no serious</td>
<td>no serious</td>
<td>no serious</td>
<td>none</td>
<td>none</td>
<td>none</td>
</tr>
</tbody>
</table>

#### Adverse effects leading to withdrawal

<table>
<thead>
<tr>
<th>Trials</th>
<th>Randomized</th>
<th>Limitations</th>
<th>Indirectness</th>
<th>Inconsistency</th>
<th>Imprecision</th>
<th>RR</th>
<th>CI</th>
<th>Study Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>no evidence available</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>0</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>1</td>
<td>randomized</td>
<td>no serious</td>
<td>no serious</td>
<td>no serious</td>
<td>no serious</td>
<td>none</td>
<td>none</td>
<td>none</td>
</tr>
</tbody>
</table>

---

2. In the majority of included trials more than 30% of patients failed to complete the study, plus dropouts were not equally distributed in some studies.
3. Heterogeneity exceeds 50% (I²-squared=50.5%).
4. The group of SSRIs has additionally been compared with that of tricyclic and related antidepressants. See details in the Additional evidence that was not graded section.
6. Another systematic review was carried out by Kirsch et al (2008). It included data on all clinical trials submitted to the US Food and Drug Administration (FDA) for the licensing of 4 new-generation antidepressants. This analysis found that drug–placebo differences increased as a function of initial severity. See details in the Additional evidence that was not graded section.
7. Arroll et al (2005) and colleagues, who carried out a systematic review of studies comparing SSRIs with placebo conducted in the primary health care, included 4 trials that showed a statistically significant advantage of SSRIs over placebo (RR 1.37, 95% CI 1.21 to 1.55).
9. From Table 15 of FDA analysis Laughren (2006). The total number of included studies is not reported.
10. Studies were not primarily designed to assess the risk of suicide-related outcomes.
11. This is a rare outcome that has been inconsistently reported in the included studies.
12. Adults with any psychiatric disorders were included.

---

**Additional information that was not GRADEd**
Antidepressants (Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors) in treatment of adults with depression

SEVERITY OF DEPRESSION

Kirsch et al (2008) obtained data on all clinical trials submitted to the US Food and Drug Administration (FDA) for the licensing of the four new-generation antidepressants. It included data on all clinical trials submitted to the US Food and Drug Administration (FDA) for the licensing of 4 new-generation antidepressants. Meta-analytic techniques were applied to assess linear and quadratic effects of initial severity of depression on improvement scores for drug and placebo groups and on drug–placebo difference. It found that drug–placebo differences increased as a function of initial severity, rising from virtually no difference at moderate levels of initial depression to a relatively small difference for patients with very severe depression, reaching conventional criteria for clinical significance only for patients at the upper end of the very severely depressed category.

The results of this analysis, together with the information that the vast majority of randomized trials assessing the efficacy of TCA and SSRIs have been carried out in populations of patients with moderate to severe depression, have led most treatment guidelines to recommend drug treatment in patients with depression of at least moderate severity.

DIFFERENCE BETWEEN TCA AND SSRI

The group of SSRIs has been compared with that of TCAs in several randomized trials. Geddes et al (2007), who conducted a Cochrane review to examine the relative efficacy of SSRIs compared to any other antidepressants included 98 trials (5044 patients treated with an SSRI or related drug, and 4510 treated with an alternative antidepressant). It found a standardized effect size for SSRIs and related drugs together versus alternative antidepressants of 0.035 (95% CI -0.006 to 0.076). The authors concluded that there are no clinically significant differences in effectiveness between SSRIs and TCAs. In terms of treatment acceptability, Barbui et al (2007), who assessed the comparative tolerability of SSRIs and tricyclic/heterocyclic antidepressant drugs, included 136 studies. The analysis showed that, compared with the tricyclic/heterocyclic group, the SSRIs showed a relatively modest advantage in terms of participants dropping out (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). In the elderly, Mottram et al (2006) analysed 29 studies that assessed the comparative beneficial and harmful effects of antidepressant classes. It found that TCAs compared less favourably with SSRIs in terms of numbers of patients withdrawn irrespective of reason (RR 1.24, CI 1.04, 1.47) and number withdrawn due to side effects (RR: 1.30, CI 1.02, 1.64).

USE DURING PREGNANCY AND LACTATION

NICE (2007) has recently provided guidance on the use of antidepressants during pregnancy and lactation.

According to NICE:
(a) The risks of taking TCAs during pregnancy and when breastfeeding are better established than those of newer drugs, although the issues of tolerability and risk in overdose remain.
(b) TCAs, such as amitriptyline, imipramine and nortriptyline, have lower known risks during pregnancy than other antidepressants.
Antidepressants (Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors) in treatment of adults with depression

(c) Fluoxetine is the SSRI with the lowest known risk during pregnancy.
(d) Most TCAs have a higher fatal toxicity index than SSRIs.
(e) SSRIs taken after 20 weeks' gestation may be associated with an increased risk of persistent pulmonary hypertension in the neonate.
(f) Paroxetine taken in the first trimester may be associated with fetal heart defects.
(g) All antidepressants carry the risk of withdrawal or toxicity in neonates; in most cases the effects are mild and self-limiting.
(h) Most antidepressants appear in some concentration in breast milk although the effects on the infant are not well understood.

Reference List


Antidepressants (Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors) in treatment of adults with depression


**From evidence to recommendations**

<table>
<thead>
<tr>
<th>Factor</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Narrative summary of the evidence base for</td>
<td>In terms of proportion of individuals showing an improvement in depressive symptoms, there is evidence that both TCAs (response analysis: RR 1.26, 1.12 to 1.42, absolute risk difference 12.2%) and SSRIs (lack of response analysis: RR 0.73, 0.69 to</td>
</tr>
</tbody>
</table>
Antidepressants (Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors) in treatment of adults with depression

| the scoping question | 0.78 absolute risk difference 17.9% were significantly more effective than placebo.  
In terms of functioning, no meta-analysed evidence was available.  
In terms of acceptability profile, there is consistent evidence that both TCAs (RR 2.35, 1.69 to 3.46) and SSRIs (RR 2.45, 2.08 to 2.89) significantly increased the risk of withdrawal due to adverse effects. |
| Summary of the quality of evidence | The quality of evidence was LOW for studies of both TCAs and SSRIs. |
| Additional evidence (eg related evidence that was not scoped ) | Available evidence suggests that the drug-placebo difference increases as a function of initial severity, rising from virtually no difference in mild depression to a relatively small difference for adults with moderate depression and a medium difference in severe depression (see additional evidence that was not graded).  
In terms of efficacy, there is unlikely a clinically important difference between TCAs and the SSRIs (see additional evidence that was not graded).  
In terms of tolerability, there is consistent evidence of a very small advantage in favour of the SSRIs (see additional evidence that was not graded). |
| Balance of benefits versus harms | In studies carried out in individuals with moderate to severe depressive episode, both TCAs and SSRIs are associated with a beneficial effect.  
In comparison with placebo, both TCAs and SSRIs are associated with an increase in the risk of adverse events leading to treatment discontinuation. Differences between the 2 types of drugs in terms of adherence are so small that they are unlikely clinically important. |
| Define the values and preferences including any variability and human rights | Clinicians should assess psychosocial stressors (e.g. domestic abuse, unemployment) associated with depression and include appropriate psychosocial interventions in their treatment plan . |
Antidepressants (Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors) in treatment of adults with depression

### Issues

| Define the costs and resource use and any other relevant feasibility issues | Diagnosis of depression and its different levels of severity is a challenge.  
In many low and middle income countries, continuous availability of psychotropics in non-specialized health care is a challenge.  
Both generic TCAs and many generic SSRIs are associated with low acquisition costs.  
Amitriptyline (as a representative of the TCAs) and fluoxetine (not as a representative of SSRIs) are included in the WHO list of essential medicines for the treatment of depressive disorders. |

### Final recommendation

- **Antidepressants** should not be considered for the initial treatment of adults with mild depressive episode.  
  Strength of recommendation: STANDARD

- **Tricyclic antidepressants (TCA) or fluoxetine** should be considered in adults with moderate to severe depressive episode/disorder.  
  Strength of recommendation: STANDARD

- If drug treatment is required in older people, **tricyclic antidepressants (TCA)** should be avoided if possible.  
  Strength of recommendation: STANDARD

- If drug treatment is required in women with depressive episode who are planning a pregnancy or pregnant or breastfeeding, **tricyclic antidepressants (TCA) or fluoxetine** should be considered  
  Strength of recommendation: STANDARD

### Limitations

The relative efficacy and tolerability of tricyclic antidepressants in comparison with the selective serotonin reuptake inhibitors, and the relationship between severity of depression and antidepressant effect, were analysed only descriptively, but were not assessed with GRADE.
Antidepressants (Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors) in treatment of adults with depression

Update of the literature search – June 2012

In June 2012 the literature search for this scoping question was updated. The following systematic reviews were found to be relevant without changing the recommendation:


